Tansu Bahar Gürbüz

article 2025

A novel marker in the ovarian preservation approach to endometrial cancer: systemic immune inflammatory index

·doi:10.61622/rbgo/2025rbgo59

Objective: This study aims to to evaluate the frequency of ovarian involvement in endometrial cancer patients aged 50 years and younger, identify associated clinicopathological factors, and uniquely assess the role of the Systemic Immune-In…

article 2025

Impact of endometrioma management strategies on ovarian reserve over the follow-up period, a prospective longitudinal study

Frontiers in endocrinology ·doi:10.3389/fendo.2025.1631108

BACKGROUND: The effects of current treatment options for endometrioma on ovarian reserve remain controversial. Recent advancements in surgical techniques may challenge the previously established evidence regarding the detrimental effects of…

rct 2025

Norethindrone acetate versus dienogest for pain relief in endometriosis related pain: A randomized controlled trial

European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/j.ejogrb.2025.113940

OBJECTIVE: To determine which progestin, norethindrone acetate (NETA) or dienogest, is more effective in alleviating pain associated with endometriosis? STUDY DESIGN: This single-center, prospective, randomized trial included 70 patients a…

article 2023

P-338 Preliminary results of the DINE Study (Dienogest vs. Norethindrone Acetate in Endometriosis Treatment)

·doi:10.1093/humrep/dead093.696

Abstract Study question How do the two-progestin type NETA and dienogest affect on pain and recurrence in patients with endometriosis? Summary answer NETA and dienogest are progestin derivatives that have similar effects on pain and recurre…